Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 6;15(4):1022.
doi: 10.3390/cancers15041022.

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape

Affiliations
Review

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape

Núria Mulet-Margalef et al. Cancers (Basel). .

Abstract

About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability-high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and in contrast to other colorectal cancer phenotypes, a significant subset of dMMR/MSI-H cancer patients strongly benefit from immunotherapy. Yet, a large proportion of these tumors remain unresponsive to any immuno-modulating treatment. For this reason, current efforts are focused on the characterization of resistance mechanisms and the identification of predictive biomarkers to guide therapeutic decision-making. Here, we provide an overview on the new advances related to the diagnosis and definition of dMMR/MSI-H status and focus on the distinct clinical, functional, and molecular cues that associate with dMMR/MSI-H colorectal cancer. We review the development of novel predictive factors of response or resistance to immunotherapy and their potential application in the clinical setting. Finally, we discuss current and emerging strategies applied to the treatment of localized and metastatic dMMR/MSI-H colorectal tumors in the neoadjuvant and adjuvant setting.

Keywords: colorectal cancer; immunotherapy; microsatellite instability; mismatch repair.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Molecular features of immune infiltrated or immune excluded dMMR/MSI-H CRC. Immune infiltrated tumors are characterized by increased PD-L1 and CTLA-4 expression as well as elevated neoantigen presentation. Immune excluded tumors feature a TGF-beta enriched tumor microenvironment with abundant immunosuppressive myeloid cells and fibroblasts. Arrow in blue box means increased. dMMR: deficient mismatch repair. MSI-H: high microsatellite instability. PD-L1: programmed death ligand 1. CTLA-4: cytotoxic T-lymphocyte antigen. MHC I: major histocompatibility complex 1. TIGIT: T cell immunoglobulin and ITIM domain. TMB: tumor mutational burden. CMS1: consensus molecular subtype 1.

References

    1. Li J. Digestive Cancer Incidence and Mortality among Young Adults Worldwide in 2020: A Population-Based Study. World J. Gastrointest. Oncol. 2022;14:278–294. doi: 10.4251/wjgo.v14.i1.278. - DOI - PMC - PubMed
    1. Muzny D.M., Bainbridge M.N., Chang K., Dinh H.H., Drummond J.A., Fowler G., Kovar C.L., Lewis L.R., Morgan M.B., Newsham I.F., et al. Comprehensive Molecular Characterization of Human Colon and Rectal Cancer. Nature. 2012;487:330–337. doi: 10.1038/nature11252. - DOI - PMC - PubMed
    1. Fishel R. Mismatch Repair. J. Biol. Chem. 2015;290:26395–26403. doi: 10.1074/jbc.R115.660142. - DOI - PMC - PubMed
    1. Vilar E., Gruber S.B. Microsatellite Instability in Colorectal Cancer-the Stable Evidence. Nat. Rev. Clin. Oncol. 2010;7:153–162. doi: 10.1038/nrclinonc.2009.237. - DOI - PMC - PubMed
    1. Boland C.R., Goel A. Microsatellite Instability in Colorectal Cancer. Gastroenterology. 2010;138:2073–2087.e3. doi: 10.1053/j.gastro.2009.12.064. - DOI - PMC - PubMed